Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.90 Insider Own1.45% Shs Outstand26.33M Perf Week-13.69%
Market Cap10.42M Forward P/E- EPS next Y-0.73 Insider Trans16.47% Shs Float26.31M Perf Month-25.99%
Income-23.76M PEG- EPS next Q-0.22 Inst Own5.81% Short Float / Ratio2.41% / 3.04 Perf Quarter-32.75%
Sales0.00M P/S- EPS this Y-7.63% Inst Trans26.17% Short Interest0.63M Perf Half Y-39.05%
Book/sh0.34 P/B1.14 EPS next Y18.28% ROA-86.75% Target Price6.00 Perf Year-52.43%
Cash/sh0.48 P/C0.82 EPS next 5Y- ROE-116.18% 52W Range0.36 - 1.39 Perf YTD-38.10%
Dividend- P/FCF- EPS past 5Y93.27% ROI-260.52% 52W High-71.94% Beta2.92
Dividend %- Quick Ratio2.09 Sales past 5Y-22.42% Gross Margin30.96% 52W Low8.36% ATR0.04
Employees14 Current Ratio2.09 Sales Q/Q- Oper. Margin0.00% RSI (14)23.52 Volatility9.85% 7.62%
OptionableNo Debt/Eq0.00 EPS Q/Q-87.34% Profit Margin- Rel Volume0.66 Prev Close0.40
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume208.83K Price0.39
Recom1.00 SMA20-22.11% SMA50-24.10% SMA200-34.32% Volume138,484 Change-2.79%
Date Action Analyst Rating Change Price Target Change
Nov-19-20Initiated Maxim Group Buy $8
Dec-05-23 07:00AM
Nov-30-23 04:30PM
Nov-29-23 09:00AM
Nov-28-23 09:00AM
Nov-14-23 09:00AM
10:24AM Loading…
Nov-10-23 10:24AM
Nov-08-23 04:00PM
Nov-01-23 07:00AM
Oct-31-23 09:00AM
Oct-30-23 09:00AM
Oct-25-23 09:00AM
Oct-24-23 09:00AM
Oct-09-23 09:00AM
Oct-05-23 09:00AM
07:00AM Loading…
Oct-04-23 07:00AM
Oct-03-23 07:00AM
Sep-27-23 09:00AM
Sep-26-23 09:00AM
Sep-21-23 09:35AM
Sep-20-23 09:00AM
Sep-19-23 09:00AM
Sep-12-23 09:00AM
Sep-11-23 09:00AM
Aug-31-23 09:00AM
Aug-29-23 09:00AM
Aug-28-23 09:00AM
Aug-11-23 12:47PM
Aug-10-23 09:00AM
Aug-09-23 04:00PM
09:00AM Loading…
Jul-26-23 09:00AM
Jul-24-23 09:00AM
Jul-20-23 09:00AM
Jul-10-23 09:00AM
Jun-28-23 09:00AM
Jun-27-23 10:15AM
May-31-23 09:00AM
May-25-23 09:00AM
May-24-23 04:32PM
May-15-23 09:00AM
May-09-23 09:00AM
May-04-23 04:00PM
Apr-26-23 09:00AM
Apr-25-23 09:00AM
Apr-17-23 09:00AM
Apr-06-23 10:00AM
Apr-05-23 01:30PM
Mar-30-23 11:00AM
Mar-27-23 07:08AM
Mar-23-23 04:00PM
Mar-15-23 09:00AM
Mar-09-23 09:00AM
Mar-06-23 09:00AM
Feb-27-23 09:00AM
Feb-15-23 09:00AM
Feb-08-23 09:00AM
Feb-07-23 09:00AM
Jan-26-23 09:00AM
Jan-25-23 11:00AM
Jan-04-23 09:00AM
Dec-20-22 09:00AM
Dec-07-22 04:00PM
Nov-28-22 10:15AM
Nov-11-22 05:46AM
Nov-09-22 04:00PM
Oct-31-22 10:33AM
Oct-26-22 09:00AM
Oct-11-22 09:00AM
Oct-06-22 09:00AM
Sep-07-22 09:00AM
Sep-01-22 09:00AM
Aug-18-22 10:27AM
Aug-17-22 09:29AM
Aug-10-22 09:13AM
Aug-09-22 06:30AM
Aug-03-22 04:00PM
Jul-28-22 09:00AM
Jul-26-22 09:00AM
Jul-08-22 02:34PM
Jun-13-22 09:00AM
Jun-07-22 09:00AM
May-25-22 01:47PM
May-24-22 09:00AM
May-23-22 11:00AM
May-04-22 09:00AM
Apr-27-22 04:00PM
Apr-26-22 11:39AM
Apr-19-22 09:00AM
Apr-18-22 05:52PM
Apr-12-22 09:00AM
Mar-22-22 09:00AM
Mar-21-22 09:00AM
Mar-16-22 09:00AM
Mar-14-22 09:00AM
Mar-10-22 09:00AM
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKee Kelly T. Jr.Chief Medical OfficerSep 25Buy0.529,6535,02028,838Sep 27 04:33 PM
DODD DAVID APresident, CEOAug 25Buy0.5735,08720,000148,957Aug 28 04:05 PM
Reynolds MarkCFOAug 18Buy0.5210,0005,17978,184Aug 21 08:39 AM
DODD DAVID APresident, CEOApr 24Buy0.6432,00020,445113,870Apr 25 03:13 PM
Reynolds MarkCFOApr 20Buy0.638,0005,04068,184Apr 21 08:38 AM